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Summary
Elevated expression of polo-like kinase1 (Plk1) has been reported in many human tumors, and inhibition of Plk1 activity
results in their mitotic arrest and apoptosis. Here we describe the profile of ON01910, a small molecule inhibitor of Plk1
activity, which induces mitotic arrest of tumor cells characterized by spindle abnormalities leading to their apoptosis. This
compound was not ATP-competitive, but competed for the substrate binding site of the enzyme. In vivo, this compound
did not exhibit hematotoxicity, liver damage, or neurotoxicity, and was a potent inhibitor of tumor growth in a variety of
xenograft nude mouse models. ON01910 showed strong synergy with several chemotherapeutic agents, often inducing
complete regression of tumors.S I G N I F I C A N C E
Plk1, which is important for cell cycle progression through mitosis, is overexpressed in many tumor cells. Patients with high levels of
Plk1 expression in their tumors were found to have a significantly poorer rate of survival than those with low levels of Plk1. Downregu-
lation of Plk1 activity in tumor cells results in mitotic arrest characterized by spindle abnormalities and apoptosis. This report describes
the antitumor activity of a small molecule inhibitor of Plk1, ON01910, and presents preclinical evidence of its low toxicity and efficacy
in animal tumor models, both as a single agent and in synergistic combination with other chemotherapeutic agents. Based on the
very desirable therapeutic index, ON01910 has entered Phase I clinical trials for cancer therapy.Introduction
Cell cycle progression is orchestrated by Cyclin/CDK com-
plexes, which are formed at specific stages of the cell cycle,
and whose activities are required for progression through S
phase and mitosis (Malumbres and Barbacid, 2001; Sherr and
McCormick, 2002; Blagosklonny and Pardee, 2003). In addition
to CDKs, several other families of protein kinases play a critical
role in cell cycle progression. These include Aurora kinases,
the NIMA family of kinases, the Mps1 gene product, and the
Polo family of protein kinases (Reviewed in Hinchcliffe and
Sluder, 2001).
The first member of the Plk gene family, POLO, was iden-
tified in Drosophila melanogaster and is a serine/threonine ki-
nase required for mitosis (Fenton and Glover, 1993; Glover,
2005). Following the discovery of POLO, members of this gene
family were identified in yeast, C. elegans, Xenopus laevis,
mouse, and human (Kitada et al., 1993; Ohkura et al., 1995;
Ouyang et al., 1999; Chase et al., 2002; Kumagai and Dunphy,
1996; Duncan et al., 2001; Donohue et al., 1995; Lake and Jeli-
nek, 1993; Simmons et al., 1992; Hamanaka et al., 1995; Li et
al., 1996). Members of this protein family are characterized by
the presence of a conserved C-terminal domain, termed the
POLO box, in addition to the kinase domain. Mutations in the
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(Fenton and Glover, 1993; Nigg, 1998).
Mammalian cells contain at least four members of this family,
termed Plk1, Plk2 (also known as Snk), Plk3 (also known as
Prk/Fnk), and Plk4 (also known as Sak) (Donohue et al., 1995;
Hamanaka et al., 1995; Simmons et al., 1992; Fode et al.,
1994). Of these, Plk1 has been the most extensively studied
member of the family and is important for numerous aspects
of mitotic progression, including centrosome maturation (Lane
and Nigg, 1996), proper assembly of mitotic spindle (Sunkel
and Glover, 1988), and activation of the anaphase promoting
complex (Kotani et al., 1998). Ectopic overexpression of Plk1
in NIH/3T3 cells results in their transformation (Smith et al.,
1997), and Plk1 mRNA and protein are overexpressed in many
tumor cells, including breast, ovarian, non-small cell lung,
head/neck, colon, endometrial and esophageal carcinomas,
and leukemias, as well as carcinogen-induced rat tumors (Wolf
et al., 1997; Knecht et al., 1999; Tokumitsu et al., 1999; Knecht
et al., 2000; Strebhardt et al., 2000; Takai et al., 2001). More
importantly, it has been shown that patients with esophageal
carcinoma with a high level of Plk1 expression have a signifi-
cantly poorer rate of survival than those with low levels of Plk1
expression (Knecht et al., 1999). In addition, it has been shown
that downregulation of Plk1 activity using antibodies (Kotani et
al., 1998), dominant negative mutants (Cogswell et al., 2000),C. DOI 10.1016/j.ccr.2005.02.009 275
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or small interfering RNAs (Spankuch-Schmitt et al., 2002a, Liu
and Erikson, 2003) results in mitotic arrest characterized by
spindle abnormalities and apoptosis. In contrast to Plk1, other
members of this family, such as Plk3, appear to function as
growth suppressor genes (Dai and Cogswell, 2003; Conn et al.,
2000), as suggested by their lack of expression in tumor tis-
sues (Dai and Cogswell, 2003). Consistent with its role as a
growth suppressor gene, ectopic overexpression of Plk3, but
not that of a kinase-defective mutant, caused growth arrest
and apoptosis of normal fibroblasts (Dai and Cogswell, 2003).
Here, we describe the profile of ON01910, a small molecule
inhibitor of Plk1 that induces mitotic arrest in a wide range of
tumor cells, characterized by spindle abnormalities leading to
apoptotic death. This compound, which exhibits very little or
no toxicity, was found to be a potent inhibitor of tumor growth
in several animal models, and showed a high degree of syner-
gism with several chemotherapeutic agents currently used in
cancer therapy, often inducing complete regression of tumors.
Results
Derivation of a small molecule inhibitor of Plk1
We have recently described the synthesis of a family of novel
small molecule kinase inhibitors that are unrelated to ATP
(Reddy and Reddy, 2002a; Reddy and Reddy, 2002b; Reddy
and Reddy, 2003) or other purine and pyrimidine nucleosides,
and which exhibit potent antitumor activity. Screening of this
novel library of molecules for antitumor activity using cell bio-
logical assays yielded several candidate molecules that ap-
peared to induce mitotic arrest of tumor cells. Further analysis
of these selected group of molecules for inhibitors of Plk1 ac-
tivity led to the identification of one compound, ON01910 (Fig-
ure 1A), that had the most potent inhibitory activity. For these
assays, 10 ng of recombinant Plk1 was mixed with different
concentrations of ON01910 or DMSO (control) and kinase as-Figure 1. Identification of novel small molecule
Plk1 inhibitor
A: Structure of the Plk1 inhibitor ON01910.
B: Plk1 inhibitory activity of ON01910. Ten nano-
grams of recombinant Plk1 was mixed with dif-
ferent concentrations of ON01910 and kinase
assays performed as described in the Experi-
mental Procedures using recombinant Cdc25C
or casein as substrates. The reaction mixtures
were subjected to SDS-PAGE and autoradiog-
raphy.
C: Plk1 assays were performed as described in
B, and the reactions spotted onto strips of P81
phosphocellulose paper, washed, and counted.
The values from individual samples were ana-
lyzed and plotted as a function of drug concen-
tration using Prism 4 Graphpad software.
D: Inhibition of mammalian Plk1 activity by
ON01910. A synchronized population of HeLa
cells at the midmitotic phase was used for the
preparation of cell lysates and Plk1 immuno-
precipitated from the clarified cell lysates as de-
scribed in the Experimental Procedures. The pre-
cipitates were washed and the kinase assays
performed in the presence of increasing con-
centrations of ON01910 as described in B using
recombinant Cdc25C or casein as substrates.276says performed using Casein or Cdc25C as substrates. SDS-
PAGE analysis of the reaction mixture showed that ON01910
is a potent inhibitor of Plk1 (Figure 1B). To determine the IC50
values, Plk1 assays were performed as described above, and
the reaction mixture spotted onto strips of P81 phosphocellu-
lose paper, washed, and counted. The values from individual
samples were analyzed and plotted as a function of inhibitor
concentration using Prism 4 Graphpad software for Macintosh.
These studies revealed that ON01910 inhibits Plk1 with an IC50
of 9–10 nM. To ascertain that this inhibition was not restricted
to recombinant Plk1, we examined the effects of ON01910 on
the enzyme activity of Plk1 immunoprecipitated from a syn-
chronized population of HeLa cells at midmitotic phase. Kinase
assays performed with these immunoprecipitates (Figure 1D)
again showed that ON01910 is a potent inhibitor of HeLa cell-
derived Plk1, and the degree of inhibition seen with this pre-
paration was similar to that seen with recombinant Plk1. It is
interesting to note that when Cdc25C was used in these as-
says as a substrate, a residual level of phosphorylation was
seen even in the presence of 1 µM ON01910, suggesting the
existence of a residual level of kinase activity in the immuno-
precipitates that is insensitive to ON01910. This may be due to
contaminating kinases such as Chk1/2, which are known to
interact with Plk1 and are capable of phosphorylating Cdc25C.
We could also demonstrate the inhibition of Plk1 by ON01910
using a commercially available ELISA-based assay kit, the re-
sults of which are presented in Supplemental Figure S1.
Steady-state kinetic analysis of Plk1
inhibition by ON01910
To define the biochemical mechanism of action of ON01910,
we examined the effects of increasing concentrations of ATP
or substrate on the inhibitory activity of the compound using
steady-state analysis. Ten nanograms of recombinant Plk1 was
mixed with different concentrations of ON01910 and incubated
at room temperature, followed by the addition of a reactionCANCER CELL : MARCH 2005
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ATP. Following termination of the reaction, the reaction mixture
was spotted onto phosphocellulose strips, which were washed
and counted. The values from individual samples were ana-
lyzed and plotted as a function of inhibitor concentration using
Prism 4 Graphpad software (Figure 2A), and values for Km
(1.988 µM) and Vmax (76.72 µM/min/mg protein) were obtained
by fitting the data to the Michaelis-Menton equation (Cleland,
1977) (Figure 2B). These analyses showed that the velocity of
substrate phosphorylation was unaltered in the presence of
increasing concentrations of ATP, and the IC50 values for the
inhibitor remained between 9 and 10 nM, suggesting that
ON01910 is not an ATP-competitive inhibitor. We next exam-
ined the effects of increasing concentrations of substrate on
the inhibitory activity of the compound in the presence of a
constant amount of ATP (100 µM). Our studies (Figures 2C and
2D) showed that increasing the concentration of the substrate
resulted in increased substrate phosphorylation in the pres-
ence of the inhibitor. Data analysis using the Michaelis-Menton
equation (Cleland, 1977) demonstrated that the maximal veloc-
ity of Plk1 was not significantly affected by the inhibitor, while
the apparent values for Km were significantly increased. The
increase in Km, combined with unchanged Vmax in the presence
of an inhibitor, is characteristic of competitive inhibition. The
IC50 values for the inhibition of Plk1 enzyme activity (Figures
2A–2D) demonstrate the substrate-dependent and ATP-inde-
pendent nature of inhibition.Figure 2. Steady-state kinetic analysis of PLK1 inhibition by ON01910
A: Ten nanograms of recombinant Plk1 was mixed with different concentrations of ON01910 and kinase assays performed in the presence of varying
concentrations of ATP as described in Figure 1C. The values from individual samples were analyzed and plotted as a function of inhibitor concentration
using Prism 4 Graphpad software.
B: Representative Michaelis-Menton curves with curve fit derived by nonlinear regression are shown.
C and D: IC50 curves (C) and Michaelis-Menton curves (D) for Plk1 in the presence of varying concentrations of Cdc25C substrate and ON01910 were
generated as described in A and B.CANCER CELL : MARCH 2005We next examined the inhibitory effects of ON01910 on a
panel of serine/threonine and tyrosine kinases. These studies
showed that at slightly higher concentrations, ON01910 exhib-
its inhibitory activity against three other kinases tested, the
PDGF receptor (PDGFR), Abl, and Flt-1. At 10- to 20-fold higher
concentrations, we also observed inhibition of CDK1, Plk2, Src,
and Fyn (Supplemental Table S1). These results suggest a
common feature shared between these kinases in their sub-
strate binding sites. Of these different kinases, ON01910 was
most active against Plk1, which is likely to be its primary target.
In vivo effects of ON01910 on Plk1 activity
Because inhibition of Plk1 synthesis or activity induced tumor
cell death preceded by mitotic catastrophe (Reviewed in Dai
and Cogswell, 2003), it was of interest to test the effect of
ON01910 on the cell cycle progression, growth, and viability of
human tumor cells. We tested the activity of ON01910 against
94 different tumor cell lines, and interestingly, this compound
was found to induce apoptosis of all of these cell lines with a
GI50 that ranged between 50–200 nM. (Selected data is shown
in Table 1.) This compound was also tested by the National
Cancer Institute, through its Developmental Therapeutics Pro-
gram (DTP), against their panel of 57 human cancer cell lines
(Grever et al., 1992). Their results showed that ON01910 had a
broad-spectrum activity and inhibited the growth of all of the
tested cell lines, including drug-resistant (MDR) cell lines, at
nanomolar concentrations (data not shown). To further investi-277
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Tumor cell line Tumor type IC50 (nM)
BT20 Breast (ER−) 80
MCF-7 Breast (ER+) 50
T47D Breast (ER+) 170
DU145 Prostate (AR−) 200
PC-3 Prostate (AR+) 150
MIA-PaCa2 Pancreatic 150
U87 Glioblastoma 80
H157 NSCLC 80
A549 NSCLC 90
H187 SCLC 80
N417 SCLC 80
AGS Gastric 100
RF1 Gastric 50
RF48 Gastric 50
COLO-205 Colorectal 250
DLD-1 Colorectal 150
HCT15 Colorectal 125
SW480 Colorectal 170
Bel-7402 Hepatoma 100
DND-1A Melanoma 75
KB Nasopharyngeal 70
Drug-resistant cell lines and their normal counterparts
MES-SA Sarcoma 100
MES-SA/DX5 Resistant sarcoma 100
CEM Leukemic 100
CEM/C2 Resistant leukemic 50
Normal cell lines
HFL Fibroblastic >10,000
PrEC Prostate epithelial >10,000
HMEC Mammary epithelial >5,000
HUVEC Umbilical vein endothelial >10,000gate the activity of this compound against MDR-positive tumor
types, we determined the IC50 values of ON01910 using two
classical MDR-positive, multidrug-resistant cell lines, MES-SA/
DX5 (Harker and Sikic, 1985) and CEM/C2 (Fujimori et al.,
1995). MES-SA/DX5 has been shown to express high levels of
P-glycoprotein and is resistant to a number of drugs, including
doxorubicin, paclitaxel, vincristine, vinblastine, etoposide, mi-
toxantrone, dactinomycin, and daunorubucin. The activity of
ON01910 was then compared to the activity of paclitaxel
(MDR-sensitive drug). Our results showed that while the paren-
tal cell line was very sensitive to paclitaxel (IC50 of 4 nM), the
MDR-positive subline was greater than 100-fold resistant (IC50
of 750 nM) to paclitaxel (data not shown). However, when the
two cell lines were treated with ON01910, both the parental
and the MDR-positive cell lines were equally sensitive to the
cell killing activity of the compound (Table 1). ON01910 resis-
tance to atypical multidrug resistant cells was also investigated
using the leukemic cell line CEM and its MDR+ subline CEM/
C2 (Fujimori et al., 1995), which is resistant to camptothecin,
etoposide, dactinimycin, bleomycin, mitoxantrone, doxorubicin,
and daunorubicin. Our results again showed that CEM/C2 was
highly sensitive to ON01910, suggesting that this compound
does not share any crossresistance to classical MDR and atyp-
ical MDR cell lines (Table 1).
In vivo inhibition of Plk1 activity by ON01910
Because Plk1 has been shown to be essential for progression
through mitosis and cytokinesis of many tumor cell lines, it was278of interest to examine the effects of ON01910 on these cells.
We chose to carry out these studies with HeLa cells, as they
have been used extensively by several investigators to study
the role of Plk1 in cell cycle progression. HeLa cells synchro-
nized at the G1/S boundary by incubation with aphidicolin were
released from G1 arrest by the removal of aphidicolin and rein-
cubation in fresh medium containing 10% FBS. Cells were
treated with DMSO or ON01910 for 8 hr, 12 hr, 16 hr, 20 hr,
and 28 hr following the release from G1 block and examined
for Plk1 activity and cell cycle progression. Analysis of the im-
munoprecipitates revealed that Plk1 activity is low or undetect-
able in control cells released from the G1/S block. This activity
increased with time and reached a peak between the 12 and
16 hr time points, and was downregulated by 20 hr (Figure 3A).
Plk1 assays carried out with immunoprecipitates derived from
cells treated with ON01910 showed (Figure 3A) that treatment
of cells with this compound resulted in a drastic reduction of
Plk1 activity at all stages of the cell cycle, indicating that this
compound acts as potent inhibitor of Plk1 activity in vivo. Di-
rect Western blot analysis of the cell lysates showed that the
steady-state levels of Plk1 in both ON01910 and DMSO-
treated cells were low at the 0 and 8 hr time points and reached
peak levels between 12 and 16 hr, followed by gradual down-
regulation, suggesting that the loss of Plk1 activity in
ON01910-treated cells is not due to degradation of Plk1 or in-
hibition of Plk1 synthesis. In DMSO-treated cells, cyclin B1
levels were upregulated between 12 and 16 hr, followed by
rapid downregulation as the cells exited mitosis followed by
the onset of cytokinesis (Figure 3A). In cells treated with
ON01910, cyclin B1 levels accumulated between 12 and 16 hr
and failed to be downregulated, suggesting a block in mitotic
progression and cytokinesis. The slightly lower levels of cyclinFigure 3. Effect of ON01910 on Plk1 activity and cell cycle progression of
HeLa cells
A: HeLa cells blocked at the G1/S interphase with aphidicolin were re-
leased from G1 arrest and treated with DMSO or ON01910 (250 nM) for 8,
12, 16, 20, or 28 hr. Following incubation with DMSO or ON01910, cells were
pelleted, lysed, and used for immunoprecipitation of CDK1 and Plk1. The
immunoprecipitates were used for the determination of Plk1 and CDK1
kinase activities. Total cell lysates were also subjected to direct Western
blots to determine the steady-state levels of Plk1 and Cyclin B1 and actin.
B: Aliquots of HeLa cells treated with DMSO or ON01910 as described in A
were fixed, stained with propidium iodide, and analyzed for their DNA
content by flow cytometry.CANCER CELL : MARCH 2005
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of apoptotic death in these cells. Measurement of CDK1 activ-
ity in control and 1910-treated cells revealed that like Plk1 ac-
tivity, CDK1 activity was low in cells released from the aphidi-
colin block, increased with time, reached a peak around the 16
hr time point, and was downregulated by the 20 hr time point.
ON01910-treated cells exhibited a slightly lower level of CDK1
activity, suggesting that this compound inhibits CDK1 activity,
albeit with much lower potency than Plk1.
Effect of ON01910 on cell cycle progression
of human tumor cells
Flow cytometric analysis of HeLa cells (Figure 3B) from the
above set of experiments showed that control cells released
from the aphidicolin block synchronously transited through S
phase and entered the G2/M phase between the 12 and 16 hr
time points. This was followed by cytokinesis and reentry of
cells into the G1 phase between the 16 hr and 20 hr time
points. It is interesting to note that Plk1 levels persist in cells
that have gone through cytokinesis, consistent with previously
published observations (Golsteyn et al., 1994). Incubation of
HeLa cells with ON01910 following release from the aphidicolin
block resulted in the accumulation of cells in the G2/M phase
of the cell cycle between 8 and 16 hr, followed by rapid loss of
viability. These results strongly suggest that ON01910-medi-
ated mitotic arrest leads to tumor cell death.
We next investigated the effect of ON01910 on several nor-
mal human cell lines, which included fibroblastic cells as well
as epithelial cell lines. Interestingly, these cell lines were found
to be very resistant to the apoptotic effects of ON01910, which
induced cell death only at 5–10 µM concentration (Table 1 and
Supplemental Figure S2). When human fibloblastic cells (HFLs)
were subjected to cell cycle analysis, both control and
ON01910-treated cells progressed through mitosis without any
abnormality, suggesting that ON01910 fails to block their cell
cycle progression (Supplemental Figure S2B). It is interesting
to note that previous studies using anti-sense oligonucleotides
and small interfering RNAs directed against PLK1 showed that
these agents, while readily blocking tumor cell cycle pro-
gression, failed to block cell cycle progression of normal fibro-
blasts and epithelial cell lines (Spankuch-Schmitt et al., 2002b).
These results suggest the possibility that inhibition of PLK1 ac-
tivity is more detrimental to tumor cells than normal cells. This
could be due to the compensatory effects of other Plk family
members in normal cells, a process that might be inoperative
in tumor cells.
Effect of ON01910 on spindle assembly and cytokinesis
Plk1 is now known to be concentrated at the centrosomal re-
gion during interphase, and as cell cycle progression occurs, it
associates with mitotic spindle poles. From metaphase on-
ward, Plk1 relocates to the midzone, from which the midbody
is eventually derived, as the cell goes through telophase
(Glover et al., 1996; Wianny et al., 1998; Glover et al., 1998;
Barr et al., 2004). Plk1-depleted HeLa cells were found to enter
mitosis, but accumulated in a preanaphase state characterized
by spindles that lacked focused poles and were not attached
to centrosomes (Sumara et al., 2004). The chromosomes them-
selves also did not become stably attached to the spindle (Su-
mara et al., 2004). To test whether ON01910 induces spindle
abnormalities, we examined the spindle architecture usingCANCER CELL : MARCH 2005confocal microscopy. HeLa cells blocked at the G1/S in-
terphase with aphidicolin were released from G1 arrest, treated
with DMSO or ON01910 (250 nM) for 7 or 12 hr, fixed with 4%
paraformaldehyde, and treated with FITC-conjugated anti-
α-tubulin antibody (to visualize tubulin spindles) and propidium
iodide (to visualize chromosomal DNA). Confocal laser micro-
scopy of the stained cells (Figure 4A) showed that while
DMSO-treated cells go through various phases of mitosis with-
out any abnormality, ON01910-treated cells exhibit profound
abnormalities in spindle formation, resulting in the appearance
of multipolar spindles, which leads to misalignment of chromo-
somes and complete loss of coordination in mitotic spindle as-
sembly. In ON01910-treated cells, the chromosomes do not
seem to be stably attached to the spindle, similar to the pheno-
type observed with Plk1-depleted cells (Sumara et al., 2004).
It is now known that Plk1 localizes to centrosomes during
interphase and participates in microtubule dynamics. Plk1-
depleted HeLa cells show abnormal localization of γ-tubulin,
with centrosomes often depleted of γ-tubulin (Sumara et al.,
2004). To determine the effects of ON01910 on centrosome
dynamics, HeLa cells incubated with DMSO or ON01910 for 7
or 12 hr (as described above) were stained with antibodies to
γ-tubulin and propidium iodide. As expected, in control cells,
γ-tubulin antibodies stained centrosomes that formed the cen-
ter of the spindle poles, which could be visualized at the 7 hr
and 12 hr time points following the release from the aphidicolin
block (Figure 4B). In sharp contrast, in cells treated with
ON01910, these antibodies stained multiple centriole pairs,
which seem to be randomly distributed in the area of the spin-
dle, or even outside of it. Following a 12 hr incubation in the
presence ON01910, degradation of these γ-tublin-positive
structures could be readily visualized (Figure 4B). These obser-
vations suggest that exposure of tumor cells to ON01910 re-
sults in abnormal centrosome localization and fragmentation,
which could be due to Plk1 inhibition.
A consequence of the mitotic abnormalities induced by this
agent could be the activation of apoptotic pathways in
ON01910-treated cells. To verify this possibility, HeLa cells
treated with DMSO or ON01910 for 0, 24, and 48 hr were sub-
jected to annexin V and propidium iodide staining followed by
flow cytometric analysis. As can be seen in Figure 5A, DMSO-
treated cells remain double-negative and hence viable at the
24 and 48 hr time points. On the other hand, cells treated with
ON01910 become annexin V-positive within 24 hr and become
double-positive within 48 hr of incubation, suggesting a rapid
onset of apoptosis in these cells. The activation of apoptotic
pathways could also be demonstrated by examining PARP
(Poly[ADP-ribose] polymerase-1) cleavage (Soldani and Sco-
vassi, 2002), which is a marker for caspase activation. Western
blot analysis of HeLa cell lysates treated with DMSO or
ON01910 (Figure 5B) show PARP cleavage in ON01910-treated
cells as early as 24 hr, which becomes very pronounced by 48
hr, indicating the progression of apoptosis in these cells. Analy-
sis of cell lysates for Caspase-3 activity also revealed a dra-
matic upregulation of this activity in ON01910-treated cells
(Figure 5C).
To rule out the possibility that the chromosomal abnormali-
ties induced by ON01910 are due to direct binding to β-tubu-
lins and thereby interfering with its polymerization or depolym-
erization, we conducted in vitro polymerization reactions using
ON01910. In these studies, paclitaxel, which stabilizes tubulin279
A R T I C L EFigure 4. Induction of spindle abnormalities by
ON01910 in human tumor cells
A: HeLa cells blocked at the G1/S interphase
with aphidicolin were released from G1 arrest
and treated with DMSO or ON01910 (250 nM)
for 7 or 12 hr, fixed with 4% paraformaldehyde,
and treated with an anti-α-tubulin antibody
(FITC conjugated) and propidium iodide. The
cells were analyzed by confocal laser micro-
scopy.
B: Cells treated with anti-γ-tubulin antibody and
propidium iodide.polymerization, and vinblastine, which induces tubulin depo-
lymerization, were used as controls. For these assays, purified
bovine tubulin was incubated with GTP at 37°C in the presence
of DMSO or different compounds dissolved in DMSO, and tu-
bulin polymerization was detected by measuring the absor-
bance of the solution at 340 nm over time. The results of this
study (Figure 5D) show that ON01910 had no effect on the
kinetics of tubulin polymerization, while the addition of vinblas-
tine inhibited tubulin polymerization and paclitaxel enhanced
the polymerization.
Safety pharmacology
The safety profile of ON01910 was determined in two standard
toxicology animal studies using rats and dogs (Table 2). In rats,
single doses of 300 and 600 mg/m2 produced no toxicity, and
1200 mg/m2 had only slight toxicity (anogenital staining). When
the dose was increased to 3000 mg/m2, 9 of 11 animals died.
In 7 day repeat dosing (1200 mg/m2), 2 of 13 rats died during
the dosing period. In 28 day repeat dosing, using groups of 12
male and 12 female rats, fixed daily doses of 180 mg/m2 and
450 mg/m2 were tolerated. A dose of 900 mg/m2 given twice280per week for 4 weeks was well tolerated. In dogs, acute single
doses of 2000 and 4000 mg/m2 produced gastrointestinal ef-
fects (diarrhea, flatulence), with other signs of discomfort dur-
ing dosing at 4000 mg/m2 (struggling, vocalization). In 7 day
repeat i.v. dosing, 1000 mg/m2 daily was well tolerated by
dogs. In 28 day repeat dosing, daily intravenous doses of 200
and 500 mg/m2 were well tolerated for 28 days in groups con-
sisting of 3 male and 3 female beagle dogs. A high dose group
started at 1000 mg/m2 showed no signs of toxicity after 8 days.
Based on dose escalation studies, a highest non-severe toxic
dose for this dose schedule was estimated at about 1500 to
2000 mg/m2 for 28 days. A separate group of 6 dogs treated
at 1000 mg/m2 twice per week for 4 weeks tolerated the com-
pound well without clinical problems. There was no evidence of
significant myelotoxicity, neuropathy, or cardiotoxicity in these
toxicology studies.
Effects of ON01910 on tumor growth in nude mice
We next tested the in vivo antitumor activity of ON01910 using
the nude mouse model system. Female athymic (NCr-nu/nu)
mice were injected subcutaneously with 1 × 107 Bel-7402,CANCER CELL : MARCH 2005
A R T I C L EFigure 5. Induction of apoptosis by ON01910
A: HeLa cells treated with DMSO or ON01910 for
0, 24, and 48 hr were stained using FITC-conju-
gated Annexin V and propidium iodide and
subjected to flow cytometric analysis as de-
scribed in the Experimental Procedures. R1, An-
nexin-negative and PI-positive dead cells; R2,
double-positive late apoptotic cells; R3, double-
negative live cells; R4, Annexin V-positive, PI-
negative early apoptotic cells.
B: Western blot analysis of cell lysates treated
with DMSO or ON01910 using anti-PARP antibod-
ies to assess the cleavage of PARP.
C: Levels of caspase-3 activity in DMSO and
ON01910-treated HeLa Cells. HeLa cells (106
cells/ml) were treated with 100 nM ON01910 for
24, 48, and 72 hr. The level of caspase-3 activity
was measured according to the assay condi-
tions described in the Experimental Procedures.
D: Effect of ON01910 on in vitro polymerization
of bovine brain tubulin. In vitro polymerization of
purified bovine brain in the presence of DMSO
(control), 5 M ON01910, 5 M vinblastine, or
5 µM paclitaxel was assessed as described in
the Experimental Procedures.MCF-7, or MIA PaCa human tumor cells derived from human
liver, breast, and pancreatic cancers, respectively, and the tu-
mors allowed to grow for 7–10 days to a size of 200–250 mm.
The mice were then divided into four groups, of which one
group received a dose of the vehicle alone and a second group
received a dose of ON01910. In the case of the Bel-7402 tu-
mors, the third group received a dose of oxaliplatin and the
fourth group a combination of ON01910 and oxaliplatin. The
tumor size and total body weights were then measured weekly
as described in the Experimental Procedures. In the case of
MCF-7-derived tumors, doxorubicin was used instead of oxa-
liplatin. MIA PaCa-derived tumors were treated with ON01910
or gemcitabine or a combination of ON01910 and gemcitabine
as described in Experimental Procedures, and tumor volumes
and body weights determined every third day. The results pre-CANCER CELL : MARCH 2005sented in Figures 6A, 6C, and 6E show that ON01910 readily
inhibited tumor growth in these xenograft model systems. In
all three cases, ON01910 had a better effect than the three
therapeutic agents used for comparison. More importantly,
there was no evidence of toxicity as judged by body weights
(Figures 6B, 6D, and 6F). Bone marrow colony assays from
ON01910-treated animals showed no decrease in colony for-
mation (data not shown). Most interestingly, treatment of tu-
mor-bearing mice with a combination of ON01910 and oxa-
liplatin or doxorubicin resulted in complete disappearance of
the tumor mass in these animals. Treatment with a combination
of gemcitabine and ON01910 resulted in a substantial de-
crease in tumor mass. To further verify the activity of ON01910,
the tumor masses from one control mouse (treated with PBS)
and two experimental animals (treated with ON01910) were re-281
A R T I C L ETable 2. Safety pharmacology of ON01910
Species Dose schedule IV bolus MTD mg/m2 STD/LD10 mg/m2 HNSTD mg/m2
Rats Single dose >1200 (no deaths) <3000 (9/11 died) —
Rats 7 day repeat 1200 (2/13 died) —
Rats 2× per week, 4 weeks <2100 (5/9 died) —
Rats 28 day repeat 450 (1/36 died) <900 (11/36 died) —
Rats 2×/week, 4 weeks 900 (1 of 24 died) —
Dogs Single dose >4000 2000
Dogs 7 day repeat >1000 >1000
Dogs 2× per week, 4 weeks >1000
Dogs 28 day repeat >1000 2500 1500–2000
MTD, maximum tolerated dose; STD, severely toxic dose; LD10, dose producing lethality in 10% of animals; HNSTD, highest non-severely toxic dosemoved at the end of 21 days of treatment and tumor extracts
prepared and analyzed for Plk1 and CDK1/Cyclin B1 activities.
The data presented in Figure 6G show that the control tumor
cell lysates exhibit very robust Plk1 and CDK1 activities, while
the tumor cell lysates derived from the ON01910-treated mice
had little or no Plk1 activity. CDK1 activity in the ON01910-
treated samples was reduced, but not completely eliminated.
Direct Western blot analyses revealed that tumor extracts from
both control and ON01910-treated animals had similar steady-
state levels of these two proteins. The low toxicity profile and
potent tumor inhibitory activity seen in nude mouse xenograft
assays points to the potential value of ON01910 as a safe ther-
apy for cancer.
Discussion
Recent strides made in our understanding of the molecular
changes that accompany cell transformation have established
that cancer is the result of alterations in multiple signal trans-
duction pathways. Drugs such as imatinib (also known as
Gleevec or STI571), an inhibitor of the BCR-ABL tyrosine ki-
nase (Druker and Lydon, 2000), has been a great success.
Such drugs have a very targeted application in the treatment
of a specific form of cancer with a mutation that is unique to
that cancer. In addition to BCR-ABL, imatinib has also been
found to be a potent inhibitor of PDGF receptor (PDGFR) and
c-Kit (reviewed in Druker and Lydon, 2000; Sawyers, 2004).
This crossreactivity may reflect the close structural similarity in
the ATP binding pockets of these different kinases, which has
provided new applications for this drug in the treatment of can-
cers where abnormalities in PDGFR and c-Kit expression play
a critical role (Sawyers, 2004).
Because all signaling pathways that have gone awry in a
cancer cell ultimately affect cell cycle progression, an alterna-
tive approach for cancer therapy is to develop inhibitors that
block the function of a critical molecule that is required by a
tumor cell to complete cell division. One such molecule ap-
pears to be Plk1. Named after the Drosophila polo gene, which
was identified through a recessive maternal effect lethal muta-
tion, this gene family is highly conserved throughout evolution
from yeast to man and plays a critical role in centrosome matu-
ration, progression through mitosis, and the onset of cytokine-
sis (Golsteyn et al., 1994; Glover et al., 1996; Wianny et al.,
1998; Glover et al., 1998; Barr et al., 2004; Dai and Cogswell,
2003). In human cells, it has been shown that Plk1 stimulates282the centrosome's microtubule nucleating activity upon mitotic
entry, and mutation or inhibition of Plk1 results in aberrations
in mitotic spindle formation (Glover et al., 1998; Barr et al.,
2004). Plk1-depleted cells enter mitosis, but accumulate in a
preanaphase state replete with spindle abnormalities charac-
terized by the absence of focused poles, and chromosomes
that do not become stably attached to the spindle (Sumara et
al., 2004). Plk1 also appears to facilitate recruitment of γ-tubu-
lin and activation of Asp at the centrosome, which helps focus
the microtubule ends and maintain their proximity to the
centrosome (Glover et al., 1998; Barr et al., 2004). Plk1 is also
known to activate certain functions of the anaphase-promoting
complex (APC), which triggers the destruction of Cyclin B, al-
lowing mitotic exit (Barr et al., 2004; Lane and Nigg, 1996; Ko-
tani et al., 1998). The concept that Plk1 is a potential target for
cancer therapy has been substantiated by the observations
that suppression of Plk1 expression or activity by anti-sense
oligonucleotides or siRNAs or dominant negative mutants in-
duces programmed cell death in human tumors, which is often
preceded by abnormal spindle formation (Lane and Nigg, 1996;
Cogswell et al., 2000; Spankuch-Schmitt et al., 2002a; Span-
kuch-Schmitt et al., 2002b; Liu and Erikson, 2003; Sumara et
al., 2004).
By developing small molecule inhibitors of Plk1 which target
regions outside the ATP binding site, we may avoid one of the
anticipated problems associated with kinase inhibitors, the
development of drug resistance as a result of accumulating
mutations in the ATP binding site of the kinase, as has been
observed in patients undergoing treatment with imatinib (Saw-
yers, 2004). Because selection of highly conserved mutable
residues in the ATP binding site appears to be relatively com-
mon for many kinases, it has been argued that substrate-com-
petitive inhibitors might constitute better drug candidates (Lev-
itzki, 2000). In addition, many of the kinase inhibitors that are
ATP mimetics inhibit their enzyme targets at nanomolar con-
centrations, while requiring micromolar concentration for tumor
cell growth inhibition, and this discrepancy may be related to
the need to overcome millimolar concentrations of ATP known
to exist inside the cell (Levitzki, 2000). The results presented in
this study describe the identification of a novel pharmaco-
phore, which inhibits Plk1 at a 9–10 nM concentration and is
noncompetitive to ATP. It is likely that this compound binds to
Plk1 at or near the substrate binding domain, since substrates
of Plk1 compete for the inhibitory activity of ON01910. In addi-
tion to Plk1, ON01910 was also inhibitory to Abl, Flt-1, andCANCER CELL : MARCH 2005
A R T I C L EFigure 6. Antitumor activity of ON01910
A: Nude mouse xenograft assays using Bel-7402 human tumor cells was carried out using ON01910 or oxaliplatin or a combination of the two compounds,
and tumor sizes measured weekly and the volume determined as described in the Experimental Procedures.
B: Total body weight of individual mice in the four groups was determined weekly and the average body weights plotted.
C: Nude mouse xenograft assays using MCF-7 human tumor cells using doxorubicin or ON01910 or a combination of the two compounds were carried
out, and tumor sizes measured weekly and the volume determined as described in the Experimental Procedures.
D: Total body weight of individual mice in the four groups was determined weekly and the average body weights plotted.
E: Nude mouse xenograft assays using human pancreatic tumor cells MIA-PaCa was carried out using ON01910 or gemcitabine or a combination of the
two compounds, and tumor sizes measured biweekly and the volume determined as described in the Experimental Procedures.
F: Total body weight of individual mice in the four groups was determined biweekly and the average body weights plotted. The data in A, C, and E
represent average tumor volume ± SEM, and the data in B, D and F represent average body weight ± SEM
G: Tumors excised from one control mouse (lane C) and two experimental animals treated with ON01910 (lanes 2 and 8) were minced and homogenized
in modified RIPA buffer (150 mM NaCl, 50 mM Tris-HCl [pH 7.4], 1 mM EDTA, 1 mM PMSF, 1% Triton X100, and a cocktail of protease inhibitors; Roche Applied
Science, Indianapolis) and clarified by centrifugation at 13,000 × g for 15 min at 4°C. The supernatants were immunoprecipitated with antibodies directed
against Plk1 or Cyclin B1 and the immunoprecipitates used to carry out kinase assays using casein or Histone H1 as substrates, as described in Figure 3.
Direct Western blot analysis of the tumor lysates was performed using 50 µg of the total protein.CANCER CELL : MARCH 2005 283
A R T I C L EPDGFR kinases at low nanomolar concentrations. At approxi-
mately 10- to 20-fold higher concentrations, inhibition of Src,
Fyn, and Plk2 kinases was also observed. While it is possible
that inhibition of these kinases may play a role in the pheno-
type observed in ON01910-treated cells, the fact that this com-
pound is most active against Plk1 suggests that this enzyme
is the primary target of this compound.
ON01910 induces mitotic arrest in a wide variety of human
tumor cells, characterized by spindle abnormalities leading to
their apoptotic death. Most interestingly, MDR-positive cells,
which are resistant to many commonly used chemotherapeutic
agents, were nevertheless very sensitive to the activity of this
compound. Because mutations in the ATP binding site appear
to be relatively common for many kinases, we tested whether
we could select for resistance to ON01910 in tumor cells by
culturing them in the presence of sublethal amounts of the
compound. In these experiments, we could isolate cell lines
resistant to other chemotherapeutic drugs, but none of the cell
lines exhibited increased survival to ON01910 (data not
shown). These results suggest that mutations in the ON01910
binding site are difficult to generate. A possible explanation
could be that such mutations lead to inactivation of the en-
zyme, which in turn results in the loss of tumor cell viability or
loss of growth advantage.
Our in vitro studies with normal human cell lines (PrEC, HMEC,
and HFL Cells) show that they are very resistant to the apoptotic
effects of ON01910, which is in sharp contrast to the effects seen
with tumor cell lines. This is also reflected in the very desirable
safety profile that is not often seen in conventional chemothera-
peutic agents. In rats, single doses of 300 and 600 mg/m2 of
ON01910 produced no toxicity, and 1200 mg/m2 had only
slight toxicity. There was no evidence of significant myelotoxi-
city, neuropathy, or cardiotoxicity in these toxicology studies.
In xenograft mouse model systems, this compound inhibited
the growth of a wide variety of human tumors, including liver,
breast, and pancreatic cancers. More importantly, this com-
pound was highly efficacious in combination with other chemo-
therapeutic agents such as oxaliplatin and doxorubicin, often
resulting in complete remission of the tumors in xenograft
model systems.
The low in vivo toxicity and the potent tumor inhibitory activ-
ity seen in nude mouse xenograft assays (i.e., a high therapeu-
tic index) led to Phase I trials of ON01910, which are currently
in progress. Because this compound is highly effective in vari-
ous combinations with conventional chemotherapy, the lack of
bone marrow toxicity may be beneficial for testing novel com-
binations for advanced cancers, including tumors resistant to
conventional chemotherapy. Clinical studies, which are currently
in progress, should reveal the best way to utilize ON01910 in
human cancer therapy.
Experimental procedures
Cell culture and viability assays
ON01910 was synthesized in the laboratory, and its purity and structure
were confirmed by HPLC, melting points, and NMR. Paclitaxel was
purchased from Sigma. All cell lines were grown in DMEM or RPMI (Cellgro),
supplemented with 10% fetal bovine serum (Atlas Co) and 1 unit/ml of peni-
cillin-streptomycin. Cell viability assays were performed by incubation in the
presence of the drug for 96 hr and the number of viable cells determined
by trypan blue exclusion.284Analysis of cell cycle progression and apoptosis
HeLa cells were synchronized at the G1/S boundary by aphidicolin block
as described by Heintz et al. (1983). Briefly, exponentially growing cells were
treated with aphidicholin (1 µg/ml, Sigma) for 14 hr followed by washing
thrice with normal growth medium and incubation in the presence or ab-
sence of ONO1910. At the indicated intervals, cells were collected by tryp-
sinization, washed with PBS, fixed in 70% ethanol, incubated with propid-
ium iodine (50 ug/ml) and RNase A (0.5 mg) for 30 min, and analyzed on a
Becton-Dickinson (BD) (FACScan) flow cytometer. Staining with FITC-
Annexin V was carried out as described by the manufacturer (BD Biosci-
ences). PARP cleavage assays were performed with equal amounts of total
cellular proteins that were resolved on a 10%-SDS-polyacrylamide gel, and
Western blotting analysis performed using anti-PARP antibodies (BD Biosci-
ences). Caspase 3 activity was measured using a commercial caspase-3
assay kit (CaspACE, Promega, Madison, WI). Caspase enzymatic hydrolysis
was measured by pNA liberation from Ac-DEVD-pNA upon cleavage by
DEVDase at 405 nm using a spectrophotometer.
Tubulin polymerization assays
Tubulin polymerization assays were performed using the Tubulin Polymer-
ization Assay Kit (Cytoskeleton Inc., Denver, CO) according to the manufac-
turer’s instructions. Tubulin polymerization was monitored by measuring the
change in absorbance at 340 nm for 60 min at one minute intervals at 37°C
in a Perkin Elmer HTS 7000 Plus Bioassay Reader.
Confocal microscopy
HeLa cells grown on glass coverslips were washed with PBS and fixed in
4% paraformaldehyde. The fixed cells were then treated with PBS contain-
ing 10% FBS/0.1% Triton X-100 for 45 min at room temperature followed
by washing and incubation with monoclonal anti α-tubulin antibody or anti-γ
tubulin antibody conjugated with FITC (DM1A, Sigma) for 1 hr at 37°C. The
coverslips were washed, treated with propidium iodide (1 g/ml in PBS) for
5 min, washed again, and mounted onto slides using prolong antifade solu-
tion (Molecular Probes). The stained cells were analyzed by using the in-
verted Olympus confocal microscope FluoView system with a 60× ob-
jective.
In vitro enzyme assays for Plk1
Plk1 expressed in the Sf9 cell line was purified as described by Lee and
Erikson (1997). 10 ng of recombinant Plk1 was incubated with different con-
centrations of ON01910 in a 15 µl reaction mixture (50 mM HEPES, 10 mM
MgCl2, 1 mM EDTA, 2 mM Dithiothreitol, 0.01% NP-40 [pH 7.5]) for 30 min
at room temperature. Kinase reactions were performed for 20 min at 30°C
in a volume of 20 µl (15 µl enzyme + inhibitor, 2 µl 1 mM ATP), 2 µl of γ
32PATP (40 ci), and 1 µl of recombinant Cdc25C (100 ng) or casein (1 g)
substrates. Reactions were terminated by boiling for 2 min in 20 µl of 2×
Laemmli buffer (Laemmli, 1970). Phosphorylated substrates were separated
by 18% SDS-PAGE (Laemmli, 1970). The gels were dried and exposed to
X-ray film for 3–10 min.
Filter binding assays for Plk1
Plk1 assays were performed as above. After incubation, 10 µl aliquots of
the reaction mixture were spotted onto a P81 phosphocellulose paper. The
filters were washed 3 times for 5 min each with 0.75% phosphoric acid
followed by acetone, and the radioactivity determined using a liquid scintil-
lation counter. Control samples contained appropriate amounts of DMSO.
Nonspecific binding was determined by conducting the assay in the ab-
sence of the enzyme, and the values subtracted from each of the experi-
mental values. The kinase activity is expressed as a percent of the maximal
kinase activity. Dose response curves were used for calculating IC50 values.
All assays were carried out in triplicate.
In vitro assays for Plk1 and CDK1 using cell lysates
Cells were washed with PBS and lysed in lysis buffer (25 mm HEPES, 0.1%
Triton-X-100, 300 mM NaCl, 0.5 mM DTT, 0.2 mM Na3VO4, 0.2 mm EDTA,
1.5 mM MgCl2, 20 mm β-glycerophosphate and protease inhibitor cocktail).
Following high-speed centrifugation, the cell lysates were used for various
kinase assays. For CDK1 assays, 100 g of total protein was incubated
with 5 g of anti-CDK1 or anti-cyclin B1, antibodies, and protein A agarose
for 2 hr at 4°C. The protein complexes were washed three times with lysisCANCER CELL : MARCH 2005
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EDTA, 2 mM Dithiothreitol 0.01% NP-40 [pH 7.5]). The kinase reactions
were carried out at 30°C for 20 min in 20 µl of kinase reaction buffer con-
taining 100 µM ATP, 40 µCi γ32PATP, and 1 µg of Histone H1. The reaction
was stopped by adding 2× Laemmli buffer and boiling for 5 min. The reac-
tion products were separated by 12% SDS PAGE and phosphorylated pro-
teins detected by autoradiography. For Plk1 assays, a similar protocol was
used, using anti-Plk1 antibodies for immunoprecipitation and Cdc25C (100
ng) or casein (2 µg) as substrates.
Nude mouse assays
Bel-7402 tumor models: twenty female athymic (NCR-nu/nu, Tacomic) nude
mice were injected with 1 × 107 Bel-7402 tumor cells subcutaneously, and
10–14 days later, when the tumor volumes reached 200–250 mm, the mice
were divided into four groups such that each group harbored tumors of the
same volume. ON01910 (250 mg/kg) dissolved in PBS was administered
alone or in combination with oxaliplatin (100 mg/kg) intraperitonially on al-
ternate days. Tumor measurements were done two times/week using trace-
able digital vernier calipers (Fisher). Body weight was determined during
each measurement. The animals were observed for signs of toxicity.
MCF-7 tumor model: 1 × 107 MCF-7 breast tumor cells were injected
subcutaneously and the tumors were allowed to grow to a size of 200–250
mm over a period of 10–15 days. For this breast tumor model system, estra-
diol pellets (1 mg) were implanted interscapularly 24 hr before tumor im-
plantation in the mammary fat pad. When the tumor volumes reached 200–
250 mm, the mice were divided into four groups and were treated with PBS
alone or ON01910 (250 mg/kg) dissolved in PBS or with doxorubicin (2.5
mg/kg) or a combination of ON01910 (250 mg/kg) and doxorubicin (2.5 mg/
kg) intraperitonially on alternate days. Tumor measurements (two dimen-
sions) were performed as described for the Bel-7402 tumor system.
MIA-PaCa tumor model: Forty female athymic (NCR-nu/nu, Tacomic)
nude mice were each injected with 1 × 107 MIA PaCa pancreatic tumor
cells subcutaneously, and tumors were allowed to grow to a size of 200–
250 mm over a period of 10–15 days. When the tumor volumes reached
200–250 mm, the mice were divided into four groups and were treated with
PBS alone or ON01910 (250 mg/kg) dissolved in PBS or with gemcytabine
(100 mg/kg) or a combination of ON01910 (250 mg/kg) and gemcytabine
(100 mg/kg) intraperitonially on alternate days. Tumor measurements (two
dimensions) were performed as described for the Bel-7402 tumor system.
Tumor volume was calculated using the following equation: V = Lx(S2)π/6,
where L is the longer and S is the shorter of the two dimensions.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/3/275/DC1/.
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